Literature DB >> 27009250

Acute Hepatitis B After the Implementation of Universal Vaccination in Italy: Results From 22 Years of Surveillance (1993-2014).

Maria Elena Tosti1, Valeria Alfonsi1, Eleonora Lacorte1, Alfonso Mele1, Cristina Galli2, Alessandro Remo Zanetti2, Luisa Romanò2.   

Abstract

BACKGROUND: Hepatitis B vaccination has proven to be very safe and highly effective. This study assessed the proportion of successfully vaccinated individuals among cases with acute hepatitis B, the proportion of preventable cases if individuals were vaccinated as recommended, and the reasons for failures.
METHODS: We analyzed data reported to the Italian Surveillance System for Acute Viral Hepatitis from 1993 to 2014.
RESULTS: A total of 362 of 11 311 (3.2%) cases with acute hepatitis B were vaccinated. Of the 277 cases for whom immunization data were available, 50 (18%) received a complete vaccination course according to the correct schedule and before exposure to hepatitis B virus. Molecular characterization of 17 of these cases showed that 6 were infected with S-gene mutants. Among the 10 949 unvaccinated cases, 213 (1.9%) escaped mandatory vaccination and 2821 (25.8%) were not vaccinated despite being at increased risk of infection. Among the latter, the most common risk factors were cohabitation with hepatitis B surface antigen (HBsAg) carriers, intravenous drug use, and homosexual/bisexual practices. Thirty-seven percent of the unvaccinated households with HBsAg carriers were aware of their risk. Lack of trust in the vaccination, negative attitude, and inaccurate beliefs followed by lack of or poor communication and low perceived severity of the disease were the most frequent reasons for vaccine hesitancy.
CONCLUSIONS: Development of acute disease in successfully vaccinated individuals is a rare event. Further efforts are needed to enhance the vaccine coverage rate in individuals at increased risk of infection.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  HBV; breakthrough infections; hepatitis B vaccination; surveillance; vaccination failure

Mesh:

Substances:

Year:  2016        PMID: 27009250     DOI: 10.1093/cid/ciw162

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  5 in total

Review 1.  Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma.

Authors:  Evangelista Sagnelli; Nicoletta Potenza; Lorenzo Onorato; Caterina Sagnelli; Nicola Coppola; Aniello Russo
Journal:  World J Hepatol       Date:  2018-09-27

Review 2.  Hepatitis B Vaccination: A Historical Overview with a Focus on the Italian Achievements.

Authors:  Luisa Romano'; Alessandro R Zanetti
Journal:  Viruses       Date:  2022-07-11       Impact factor: 5.818

3.  Neutralization of hepatitis B virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen.

Authors:  Ayaka Washizaki; Asako Murayama; Megumi Murata; Tomoko Kiyohara; Keigo Yato; Norie Yamada; Hussein Hassan Aly; Tomohisa Tanaka; Kohji Moriishi; Hironori Nishitsuji; Kunitada Shimotohno; Yasumasa Goh; Ken J Ishii; Hiroshi Yotsuyanagi; Masamichi Muramatsu; Koji Ishii; Yoshimasa Takahashi; Ryosuke Suzuki; Hirofumi Akari; Takanobu Kato
Journal:  Nat Commun       Date:  2022-09-05       Impact factor: 17.694

4.  Deep sequencing of hepatitis B surface antigen gene in the preserved umbilical cords in immunoprophylaxis failure against mother-to-child HBV transmission.

Authors:  Haruki Komatsu; Ayano Inui; Yasuto Suzuki; Masaya Sugiyama; Tomoo Fujisawa
Journal:  BMC Infect Dis       Date:  2019-11-21       Impact factor: 3.090

5.  The effectiveness of the national hepatitis B vaccination program 25 years after its introduction in Iran: a historical cohort study.

Authors:  Mohsen Moghadami; Nazanin Dadashpour; Ali Mohammad Mokhtari; Mostafa Ebrahimi; Alireza Mirahmadizadeh
Journal:  Braz J Infect Dis       Date:  2019-11-01       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.